The article explores the growing informal market for GLP-1 weight-loss drugs in Australia, where consumers are bypassing prescription systems to access medications through overseas clinics, social media sellers, and unapproved channels. Stories like Kansasin Darwan's highlight risks of using unregulated products, which can cause severe side effects such as dizziness, nausea, and depression. Research by the University of New South Wales reveals a surge in GLP-1 usage, with 2% of Australians now regularly taking these drugs. The Therapeutic Goods Administration (TGA) warns against importing or selling unapproved peptides, citing cases of liver injury linked to products like retatrutide. Experts stress that while legitimate medical use is increasing, the informal market poses significant health risks due to lack of oversight. Social media amplifies demand by framing these drugs as quick fixes for weight loss, overshadowing their role in treating underlying health conditions. The article underscores the need for balanced access and regulation to protect public health.

Alt: a cat is laying on its back in a pile of plastic bags staring into the void contemplating how little the world makes sense anymore and too mystified to be angry just yet at the family members who told her that college degrees and a job would set her free, with the words "grocery plans denied" in large white letters, because white people ruin everything, amirite?